

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Emini, Emilio A. et al.

Serial No. 10/507,237

Filed: September 9, 2004

For: METHOD OF INDUCING AN ENHANCED IMMUNE  
RESPONSE AGAINST HIV

Art Unit: \_\_\_\_\_

Examiner: \_\_\_\_\_

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).


2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK &amp; CO., INC.

By  Date March 14, 2005

**INFORMATION DISCLOSURE STATEMENT**

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

| RELATED APPLICATION |             |            |
|---------------------|-------------|------------|
| U. S. SERIAL NUMBER | FILING DATE | MERCK CASE |
|                     |             |            |
|                     |             |            |
|                     |             |            |
|                     |             |            |
|                     |             |            |
|                     |             |            |

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: Anna L. Cocuzzo

Attorney \_\_\_\_\_ For Applicant(s)

Reg. No. 42,452

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-1273

Date: MARCH 14, 2005

Sheet 1 of 2

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(use many sheets as necessary)

2

of

2

### COMPLETE IF KNOWN

|                        |                         |
|------------------------|-------------------------|
| Application Number     | 10/507,237              |
| Filing Date            | September 9, 2004       |
| First Named Inventor   | Emini, Emilio A. et al. |
| Group Art Unit         |                         |
| Examiner Name          |                         |
| Attorney Docket Number | 21051YP                 |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. | Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.  |
|--------------------|----------|---|
|                    |          | Barnett, S. et al. "Prime-Boost Immunization Strategies against HIV", AIDS Research and Human Retroviruses, 1998, Vol. 14, Supplement 3, pp. S-299-S-309  |
|                    |          | Chen, P. et al. "Effective repeat administration with adenovirus vectors to the muscle", Gene Therapy, 2000, Vol. 7, pp. 587-595  |
|                    |          | Huang, Y. et al. "Human Immunodeficiency Virus Type 1-Specific Immunity after Genetic Immunization Is Enhanced by Modification of Gag and Pol Expression", Journal of Virology, 2001, Vol. 75, pp. 4947-4951  |
|                    |          | Mack, C. et al. "Circumvention of Anti-Adenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate Serotype", Human Gene Therapy, 1997, Vol. 8, pp. 99-109   |
|                    |          | Mastrangeli, A. et al. "'Sero-Switch' Adenovirus-Mediated In Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype", Human Gene Therapy, 1996, Vol. 7, pp. 79-87 |
|                    |          | Morral, N. et al. "Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons", Proc. Natl. Acad. Sci. USA, 1999, Vol. 96, pp. 12816-12821                            |
|                    |          | Nan, X. et al. "Development of an Ad7 cosmid system and generation of an Ad7DE13HIVDmn env/rev recombinant virus", Gene Therapy, 2003, Vol. 10, pp. 326-336   |
|                    |          | Natuk, R. et al. "Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model", Proc. Natl. Acad. Sci., USA, 1992, Vol. 89, pp. 7777-7781  |
|                    |          | Natuk, R. et al. "Adenovirus Vectored Vaccines", Developments in Biological Standardization, 1994, Vol. 82, pp. 71-77   |
|                    |          | Natuk, R. et al. "Immunogenicity of Recombinant Human Adenovirus-Human Immunodeficiency Virus Vaccines in Chimpanzees", AIDS Research and Human Retroviruses, 1993, Vol. 9, pp. 395-404   |
|                    |          | Patterson, L. et al. "Potent, Persistent Cellular Immune Responses Elicited by Sequential Immunization of Rhesus Macaques with Ad5 Host Range Mutant Recombinants Encoding SIV Rev and SIV Nef", DNA and Cell Biology, 2002, Vol. 21, pp. 627-635                           |
|                    |          | Shiver, J. et al. "Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity", Nature, 2002, Vol. 415, pp. 331-335   |
|                    |          | Yoshida, T. et al. "Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols", Clin. Exp. Immunol., 2001, Vol. 124, pp. 445-452                    |
|                    |          |   |
|                    |          |   |

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003